Simcere Pharmaceutical Group Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Simcere Pharmaceutical Group ha aumentado sus beneficios a una tasa media anual de 20.5%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 10.4% anual. Los ingresos han ido creciendo a una tasa media de 10.4% al año. La rentabilidad financiera de Simcere Pharmaceutical Group es de 9.9%, y sus márgenes netos son de 10.8%.

Información clave

20.5%

Tasa de crecimiento de los beneficios

17.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	7.3%
Tasa de crecimiento de los ingresos	10.4%
Rentabilidad financiera	9.9%
Margen neto	10.8%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Simcere Pharmaceutical Group. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:S2P Ingresos, gastos y beneficios (CNY Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	6,608	715	2,855	1,563
30 Sep 23	6,806	1,928	2,997	1,708
30 Jun 23	6,999	3,144	3,138	1,853
31 Mar 23	6,659	2,038	2,985	1,790
31 Dec 22	6,324	931	2,835	1,728
30 Sep 22	5,952	972	2,709	1,585
30 Jun 22	5,579	1,013	2,584	1,441
31 Mar 22	5,290	1,260	2,501	1,429
31 Dec 21	5,000	1,507	2,419	1,417
30 Sep 21	4,852	1,274	2,306	1,366
30 Jun 21	4,703	1,042	2,193	1,315
31 Mar 21	4,606	856	2,088	1,228
31 Dec 20	4,509	670	1,982	1,142
30 Sep 20	4,528	699	1,990	1,030
30 Jun 20	4,548	728	1,997	918
31 Mar 20	4,792	866	2,183	817
31 Dec 19	5,037	1,004	2,368	716
31 Dec 18	4,514	734	2,512	447
31 Dec 17	3,868	350	2,433	212
30 Sep 13	2,027	193	1,328	200
30 Jun 13	2,111	42	1,413	217

Ingresos de calidad: S2P tiene un alto nivel de ganancias no monetarias.

Margen de beneficios creciente: Los actuales márgenes de beneficio(10.8%) de S2P son inferiores a los del año pasado (14.8%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lS2P han crecido significativamente en un 20.5% al año.

Acelerando crecimiento: S2P ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: S2P tuvo un crecimiento negativo de los beneficios (-23.2%) durante el año pasado, lo que dificulta la comparación con la media de la industria Pharmaceuticals (3.8%).

Simcere Pharmaceutical Group Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.36 in FY 2022)

Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022)

Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023

Full year 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.58 in FY 2021)

Recent updates

Full year 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.36 in FY 2022)

Dividend of CN¥0.16 announced

Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024

Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500

Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023

Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets

Simcere Pharmaceutical Group Limited Announces Localization Application of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug for SIM0501 (An Usp1 Small-Molecule Inhibitor) Issued by U.S. Food and Drug Administration

Simcere Pharmaceutical Group Limited and Neurodawn Pharmaceutical Co., Ltd. Obtains Clinical Trial Approval Issued by the National Medical Products Administration

Simcere Pharmaceutical Group Limited Announces Approval of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China

Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration

First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022)

Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Co-Founder recently sold €271k worth of stock

Simcere Pharmaceutical Group Limited Approves Final Cash Dividend for the Year Ended December 31, 2022, Payable on 12 July 2023

Upcoming dividend of CN¥0.16 per share at 2.3% yield

Co-Founder recently sold €360k worth of stock

Full year 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.58 in FY 2021)

Investor sentiment improves as stock rises 19%

Simcere Pharmaceutical Group Limited Announces Conditional Approval for Marketing in China of Anti-Sars-Cov-2 Innovative Drug Xiannuoxin Tm Granted by the National Medical Products Administration

Investor sentiment deteriorated over the past week

Simcere Pharmaceutical Group Limited Announces Appointment Wang Xi as an Executive Director and the Appointment of Sung Ka Woon as an Independent Non-Executive Director

Now 30% undervalued

Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application of Anti-SARS-CoV-2 Innovative Drug Xiannuoxin (Simnotrelvir Tablets/Ritonavir Tablets (Co-Packaged)) by the National Medical Products Administration

Co-Founder recently bought €957k worth of stock

Simcere Pharmaceutical Group Limited Appoints Mr. Tang Renhong as the Chairman of the Board of Directors and Chief Executive Officer of Simcere Zaiming Pharmaceutical Co., Ltd., with Effect from January 1, 2023

Simcere Pharmaceutical Group Limited Announces - the Clinical Trial Approval for SIM0348 Injection (Humanized TIGIT/PVRIG Bispecific Antibody) Issued by the National Medical Products Administration

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Announces Phase II/III Clinical Trial of Its 3Cl-Targeting anti-SARS-CoV-2 Drug Candidate Complete All Patients Enrollment

Simcere Pharmaceutical Group Limited Announces A Phase II/III Clinical Study of Anti-Sars-COV-2 Drug Candidate XIANNUOXIN (SIM0417) Complete All Patients Enrollment

Simcere Pharmaceutical Group Limited Announces A Multi-Center, Randomized, Double-Blind, Parallel and Placebo-Controlled Phase III Clinical Study

Insufficient new directors

Simcere Pharmaceutical Group Limited Announces Executive Changes

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug Application

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP

Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP

First half 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.21 in 1H 2021)

Simcere Pharmaceutical Group Limited Announces Executive and Committee Changes

Simcere Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 31, 2022

Simcere Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Cosela, the World's First Comprehensive Myeloprotection Drug Against Chemotherapy Damage, Wins Approval in China

Simcere Pharmaceutical Group Limited Announces Conditional Marketing of COSELA (Trilaciclib Hydrochloride for Injection) in China by the National Medical Products Administration

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Limited Declares Final Dividend for the Year Ended December 31, 2021, Payable on July 15, 2022

Upcoming dividend of CN¥0.15 per share

Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2021

Simcere Pharmaceutical Group Limited Announces Appointment of Tang Renhong as Co-Chief Executive Officer

Investor sentiment improved over the past week

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0417 (3Cl) Issued by the National Medical Products Administration

CFO & Executive Director recently bought €66k worth of stock

Full year 2021 earnings released: EPS: CN¥0.58 (vs CN¥0.28 in FY 2020)

Less than half of directors are independent

Simcere Pharmaceutical Group Limited Obtains Permission from the National Medical Products Administration of China to Conduct Clinical Trials

Investor sentiment improved over the past week

Vivoryon Therapeutics N.V. and Simcere Pharmaceutical Group Ltd Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease

Simcere Pharmaceutical Group Announces Primary Endpoint Met in Phase III Clinical Trial of Trilaciclib in Chinese Patients with Small Cell Lung Cancer

Simcere Pharmaceutical Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2021

Simcere Pharmaceuticals Announces Appointment of Bijoyesh Mookerjee as Chief Medical Officer, Oncology

Desglose de ingresos y gastos
Beta